SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is facing intense sell-side pressure as investors express skepticism over the company's aggressive debt-fueled expansion into AI infrastructure and the long-term conversion of its substantial cloud backlog into cash flow. While some traders view the recent descent to 52-week lows as a prime accumulation opportunity for a structural AI play, others are aggressively shorting the stock, citing management silence, credit downgrades, and concerns that demand for AI services may not materialize as projected.

Direxion Shares ETF Trust - Direxion Daily MSCI South Korea Bull 3X ETF

Direxion Daily South Korea Bull 3X Shares

KORU is facing extreme volatility as retail investors grapple with massive margin calls and a significant drawdown from its recent highs, with community discussion intensely focused on the upcoming 20-for-1 stock split and the impact of the SK Hynix IPO. Traders are deeply divided, with many debating whether the current price action represents a classic 'falling knife' or a strategic buying opportunity driven by the underlying strength of the South Korean semiconductor and memory sectors.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded by Keyvan Mohajer, Majid Seyed Emami and James M. Hom on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is facing intense scrutiny as investors debate whether the current price represents a value-driven accumulation phase or a trap, fueled by high short interest and anticipation surrounding the pending LivePerson merger. The community remains deeply divided, with bulls pointing to the company's enterprise footprint and potential short-squeeze catalysts, while bears focus on persistent dilution, cash burn, and the stock's underperformance relative to broader AI sector hype.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle is facing intense scrutiny as a viral social media trend criticizing portion sizes and higher menu prices sparks a shareholder lawsuit, weighing heavily on investor sentiment. Despite this, community debate remains split between those calling the stock a value-play at multi-year lows and critics who argue that inconsistent quality and aggressive pricing have fundamentally damaged the brand's appeal.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is facing heightened volatility as markets react to escalating geopolitical tensions in the Strait of Hormuz and concerns over a potential rate hike following hawkish commentary from Fed officials. Investors are heavily focused on upcoming CPI data, with community sentiment divided between capitalizing on short-term price swings and bracing for a broader market pullback.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is facing intense volatility as traders debate the sustainability of its AI-driven valuation, with the stock pulling back significantly from its recent highs. The community is sharply divided between those viewing the decline as a long-term accumulation opportunity for AI infrastructure and those expecting further downside as they exit positions once touted as trillion-dollar growth plays.

Factorial Energy, Inc. engages in the development and commercialization of solid-state battery technologies. Its platforms include FEST and Solstice, designed to deliver high-performance, scalable battery solutions for applications in drones, robotics, automotive, and other advanced mobility sectors. The company is headquartered in Billerica, MA.

Factorial Energy Inc. - Ordinary Shares- Class A

Factorial Energy Inc

Factorial Energy is experiencing significant volatility driven by a strategic partnership with Tulip Tech to advance solid-state battery technology for drones. While some community members view the news as a major validation of their commercial potential, others remain skeptical, leading to intense debate over the stock's long-term viability and recent price swings.

Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. It focuses on the IL-7 / TSLP receptor pathways and complement system, addressing immune dysregulation to help patients take back control of their lives. The company was founded by David Grayzel and Shelia Violette in 2017 and is headquartered in Waltham, MA.

Q32 Bio Inc.

Q32 Bio is experiencing significant volatility and trading momentum following the release of positive 36-week clinical trial data for bempikibart in treating alopecia areata. While retail traders are actively debating the potential for a short squeeze and long-term upside, caution remains high as investors monitor the impact of a recent large-scale public offering and potential dilution on the stock's future performance.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

United States Oil Fund is trending as investors react to renewed airstrikes in Iran and ongoing tensions in the Strait of Hormuz, sparking intense community debate over potential supply disruptions and energy market volatility. Market participants are actively discussing the impact of geopolitical risk premiums, with many questioning whether current price action accurately reflects the severity of the conflict or if it is being driven by algorithmic manipulation.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk Corp (SNDK) is experiencing intense volatility as investors debate the sustainability of the AI memory demand cycle amid broader semiconductor sector rotation. The stock is a primary focus for traders as community members weigh massive analyst price target revisions against concerns over cyclical peaks and the impact of broader market headwinds like geopolitical tensions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What Makes OKYO Pharma (OKYO) a New Buy Stock

OKYO Pharma (OKYO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Receives Average Rating of "Hold" from Analysts

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) has earned an average recommendation of 'Hold' from the five analysts that are presently covering the firm, MarketBeat.com reports...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Up 31.9% in April

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totaling 272,194 shares, an increase of 31.9% from the March 31st total of 206,345 shares. Based on...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Down 25.0% in March

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) was the target of a significant decrease in short interest during the month of March. As of March 31st, there was short interest...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Given Average Recommendation of "Hold" by Brokerages

Shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) have been given an average rating of "Hold" by the five analysts that are covering the firm, Marketbeat.com reports. One...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Update

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) was the target of a large drop in short interest during the month of March. As of March 13th, there was short interest totaling...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Down 12.4% in February

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) was the target of a significant drop in short interest in February. As of February 27th, there was short interest totaling 435,430...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Receives Consensus Rating of "Hold" from Analysts

Shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) have received a consensus rating of "Hold" from the five analysts that are covering the firm, Marketbeat.com reports. One...

OKYO Pharma (NASDAQ:OKYO) Raised to "Strong-Buy" at Piper Sandler

Piper Sandler raised OKYO Pharma to a "strong-buy" rating in a report on Friday...

Shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) have earned a consensus rating of "Hold" from the five ratings firms that are presently covering the firm, MarketBeat.com...

OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. It operates through the US and UK geographical segments. The company was founded on July 4, 2007 and is headquartered in London, the United Kingdom.

OKYO Pharma Limited - Ordinary Shares - New

OKYO Pharma Stock Rises After Company Outlines Development Pathway For Neuropathic Corneal Pain Drug

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$1.55
Prev Close	$1.69
Open	$1.67
Dividend Yield	N/A
50-Day Moving Average	$1.61
Beta	0.78
Avg. Volume	64,095.01
PE Ratio	-13.48

52-Week High	$3.35
52-Week Low	$1.42
Market Capitalization	$86.82M
EPS (Annual)	N/A
Price to Book	-19.03
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

OKYOPharma Limited

Latest OKYO News